((自动化翻译由路透提供，请见免责声明 ))
10月24日 - ** 基因编辑公司Intellia Therapeutics 股价下跌18%至16.38美元
** 该公司称，在一项中期研究中，其治疗遗传性血管性水肿这种罕见疾病的实验性基因疗法$(HAE)$ 与安慰剂相比，能帮助减少高达81%的每月肿胀发作次数。
** HAE的特征是皮肤、胃肠道、上呼吸道系统、面部和喉咙不可预测地频繁出现严重肿胀。
** 我们预计，考虑到体内基因编辑的潜在风险和该适应症的竞争格局，投资者会认为 HAE 发作减少 75-80% 的结果并不令人印象深刻。
** 美国目前批准的HAE治疗药物包括武田药品 和BioCryst Pharmaceuticals 生产的药物。
** 包括盘中走势在内，Intellia 的股价今年以来下跌了约 46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.